CATHETER PRECISION INC

Company Overview

Catheter Precision (VTAK) is a small medical devices company focused on electrophysiology (EP) solutions, principally the VIVO non‑invasive 3D cardiac mapping system and the LockeT sterile suture‑retention/closure device. The firm combines system sales and consumables with direct U.S. sales and international distributors, has modest revenues ($0.42M in 2024, early traction for LockeT in 2025), a very small workforce (≈22 employees), and outsources most manufacturing and certain components. Key corporate drivers are clinical adoption, regulatory clearances (FDA/CE/UKCA), R&D/IPO‑style IP acquisitions (PeriKard, CPNS assets), and concentrated customers (two buyers ≈52% of 2024 revenue), all against strong competition from large medtech players.

Executive Compensation Practices

Given constrained cash flow and recurring operating losses, executive pay at this early‑commercial medtech company is likely skewed toward equity and incentive‑based pay; filings note materially higher stock‑based compensation in 2025 tied to hires and grants. Compensation metrics management is likely to emphasize include revenue growth for LockeT and VIVO, system placements and disposable consumable volume, regulatory/clinical milestones (CE mark, trial progress), and successful financing or royalty re‑forecast outcomes that materially affect royalties payable fair value. R&D and commercialization hires (C‑level, regional sales) indicate performance bonuses or equity tied to commercial roll‑out, while limited cash and going‑concern risk mean executives may receive larger option/grant packages to conserve cash and align long‑term upside. Noteholder/royalty obligations, convertible securities, and Section 382 tax events create additional complexity that compensation committees must manage to avoid perverse incentives around near‑term financing or milestone timing.

Insider Trading Considerations

Insider trading in this company will often reflect financing activity (PIPE, ATM, warrants, convertible instruments) and tight cash runway signals — insiders may exercise options or sell shares around financings, which can move an otherwise illiquid float. Expect trading to cluster around regulatory/clinical milestones (CE/clinical results) and major commercial updates; companies in medical devices commonly impose blackout periods before such disclosures and rely on Rule 10b5‑1 plans to manage reporting risk. Related‑party notes, noteholder royalties and frequent small financings increase the likelihood of dilution events, so watch Form 4 filings for option exercises, warrant monetizations, and sales after financings; concentrated customer and key‑person risks also increase the chance that insiders with large holdings will trade to diversify. Regulatory/reporting rules (SEC Form 4, Section 16 timing, and FDA/clinical disclosure sensitivities) and the company’s going‑concern status make timely disclosure and planned trading programs particularly important to monitor.